Alkem Laboratories has completed a significant investment in its subsidiary Enzene Biosciences Limited, acquiring equity shares for ₹3 billion through a rights issue. This strategic investment increases the pharmaceutical company's stake in the biologics manufacturing subsidiary to 99.61% of Enzene's total equity share capital.

Transaction Details

The rights issue was executed with the total consideration amounting to ₹3 billion. The transaction was structured as a cash consideration deal, representing a substantial increase from the previously reported investment amount of ₹299.99 crores.

About Enzene Biosciences

Enzene Biosciences Limited operates as a subsidiary of Alkem Laboratories in the biosimilars and biologics contract manufacturing industry. The company reported a turnover of ₹363.62 crores for the financial year ended March 31, 2025, demonstrating its established presence in the biologics manufacturing sector.

Investment Rationale

The acquisition is aimed at supporting Enzene Biosciences' operational and expansion requirements. The investment will be utilized to meet the subsidiary's capital expenditure and working capital requirements, enabling the company to strengthen its manufacturing capabilities and operational infrastructure.

Regulatory Compliance

The transaction was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the acquisition does not fall within the purview of related party transactions and required no governmental or regulatory approvals for completion.

This investment reinforces Alkem Laboratories' commitment to expanding its presence in the biologics and biosimilars manufacturing space through its subsidiary Enzene Biosciences, positioning the company to capitalize on growing opportunities in the biologics contract manufacturing sector.

Alkem Laboratories Limited has disclosed receiving a GST demand order from Kerala tax authorities, marking a regulatory development that the pharmaceutical company plans to contest through legal channels.

GST Demand Details

The company received an order from the State Tax Officer, Taxpayer Services Circle, Thrippunithura Ernakulam Kerala, on December 24, 2025. The demand pertains to FY2021-22 operations under the company's Kerala GSTIN.

The demand has been raised under applicable provisions of the IGST Act, 2017, with the primary allegation being excess availment of Input Tax Credit (ITC).

Company's Response and Legal Action

Alkem Laboratories has clearly stated its disagreement with the demand order and confirmed its intention to contest the same. The company is in the process of taking appropriate actions, including filing an appeal against the order.

The pharmaceutical company emphasized that it does not agree with the allegations made in the demand order, setting the stage for a legal challenge to the tax authorities' assessment.

Financial Impact Assessment

According to the company's disclosure, there is no material impact expected on its financial, operational, or other activities. The relatively modest amount of ₹3.82 lakh appears manageable for the large-cap pharmaceutical company.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company noted that the order was received on December 24, 2025, and the intimation was submitted on the first working day following receipt of the order, demonstrating compliance with regulatory timelines.

The information has been made available on the company's website at www.alkemlabs.com , ensuring transparency for stakeholders and investors.